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ABSTRACT
Objective: The aim of this study is to select the risk factors for
local failure requiring salvage neurosurgery in patients with brain
metastases treated with stereotactic radiosurgery in a single
institution. Methods: The follow-up of 123 patients, with 255 brain
metastases treated with radiosurgery at the Radiation Oncology
Department of the Hospital Israelita Albert Einstein from July 1993
to August 2001, was retrospectively analyzed. The criteria for
salvage neurosurgery were tumor volume enlargement, or tumor
persistence leading to severe neurological symptoms, life-
threatening situation or critical steroid dependence. We considered
the case as local failure when the histopathologic evaluation
showed morphologically preserved cancer cells (tumor recurrence,
persistence or progression). We applied the Fisher’s exact test to
evaluate the statistical correlation between local failure and primary
tumor histology, volume of the brain metastases, prescribed
radiosurgery dose, and whole brain radiotherapy. Results: Fourteen
of 123 patients (11%) underwent salvage neurosurgery. Histology
showed preserved cancer cells with necrosis and/or bleeding in
11 cases (9% of the total accrual), and only necrosis with or without
bleeding (without preserved cancer cells) in three cases. The
primary tumor histology among the 11 patients considered with
active neoplasia was malignant melanoma in five cases (21% of
the patients with melanoma), breast adenocarcinoma in three
(16% of the patients with breast cancer), and other histology in the
remaining three. Breast cancer diagnosis, non-elective whole brain
irradiation, volume of the brain metastases, and the prescribed
radiosurgery dose did not correlate with the risk of local failure.
Patients treated with elective whole brain radiotherapy showed
fewer local failures, when compared to all patients receiving whole
brain radiotherapy, and to the patients not receiving this treatment,
with incidence of failure in 4%,7% and 14%, respectively, but this
difference did not reach statistical significance. Malignant
melanoma histology was the single risk factor statistically
associated with local failure, both at univariate (p = 0.0381) and
multivariate analysis (p = 0.0321). Conclusion: In our experience,
the risk of local failure after radiosurgery for brain metastases
requiring salvage neurosurgical intervention is greater in patients
with malignant melanoma, and also suggests a trend to be greater
in patients not treated with elective whole brain irradiation.
Keywords: Radiosurgery; Neoplasm metastasis/therapy; Brain
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RESUMO
Objetivo: O objetivo deste estudo é selecionar os fatores de risco
para falha local que requer neurocirurgia de resgate em pacientes
com metástases cerebrais submetidos a radiocirurgia em uma
única instituição. Métodos: Analisamos retrospectivamente a
evolução clínica de 123 pacientes com 255 metástases cerebrais
tratadas com radiocirurgia, no Departamento de Radioterapia do
Hospital Israelita Albert Einstein, entre julho de 1993 e agosto de
2001. Os critérios para indicação de neurocirurgia de resgate foram
aumento do volume tumoral ou persistência do tumor causando
quadro neurológico grave, risco de vida ou dependência de
corticosteróides. Consideramos o caso como falha local quando a
avaliação histopatológica mostrou presença de células
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neoplásicas com morfologia preservada (recidiva, persistência
ou progressão tumoral). Aplicamos o teste exato de Fisher para
avaliar a correlação estatística entre probabilidade de falha local
e histologia do tumor primário, volume das metástases cerebrais,
dose prescrita de radiocirurgia e radioterapia de cérebro total.
Resultados: Quatorze dos 123 pacientes (11%) foram submetidos
a neurocirurgia de resgate. O estudo histopatológico mostrou
células neoplásicas preservadas acompanhadas de necrose e/ou
sangramento em 11 casos (9% de todos os casos) e somente
necrose com ou sem sangramento (ausência de células
neoplásicas preservadas) em três casos. A histologia do tumor
primário dos 11 pacientes com neoplasia ativa foi melanoma
maligno em cinco casos (21% dos pacientes com melanoma),
adenocarcinoma de mama em três (16% dos pacientes com
neoplasia de mama) e outras histologias nos outros três casos.
Diagnóstico de neoplasia de mama, radioterapia de cérebro total
de forma não-eletiva, volume das lesões cerebrais e dose de
prescrição da radiocirurgia não apresentaram correlação estatística
com risco de falha local. Pacientes tratados de forma eletiva com
radioterapia de cérebro total mostraram menos falhas locais
quando comparados com todo o grupo de pacientes que receberam
radioterapia de cérebro total e com os pacientes que não
receberam este tratamento, com 4%, 7% e 14% de falha,
respectivamente; porém esta diferença não alcançou significância
estatística. Melanoma maligno como histologia primária foi o fator
isolado que mostrou correlação estatística com falha local, tanto
na análise univariada (p = 0,0381) como na multivariada (p =
0,0321). Conclusão: O risco de falha local necessitando de
neurocirurgia de resgate após radiocirurgia para metástases
cerebrais foi maior para pacientes com melanoma maligno e
também sugere uma tendência a ser maior em pacientes não
submetidos eletivamente a radioterapia de cérebro total.
Descritores: Radiocirurgia; Metástase neoplásica/terapia;
Neoplasias cerebrais; Neurocirurgia; Fatores de risco
INTRODUCTION
The treatment for patients with brain metastases
includes general measures with steroids and clinical
care, and specific measures including whole brain
radiotherapy (WBRT) and chemotherapy, and focal
treatments including stereotactic radiosurgery (SRS)
and neurosurgery (NS). Patients receiving only non-
specific clinical care survive few weeks, while those
under specific and focal treatments have their median
survival time extended for several months(1). Combined
WBRT and focal treatments, either SRS or NS, have
resulted in the best long lasting control of brain
metastases for patients with single(2) or two to four
lesions(3).
Both SRS and NS are effective methods for
achieving sustained local control in selected patients
with brain metastases. SRS is more cost-effective(4) and
less restricted by location, number of lesions,
performance status, or general medical condition(5). NS
has the advantage of faster symptom relief and provides
material for definitive histological diagnosis(6). The
choice of the best focal treatment is still not completely
defined, depending, in many cases, on the skill of the
specialized center team and on personal preference.
SRS controls more than 80% of the treated
metastatic lesions(2—13) but some cannot be locally
controlled, needing rescue NS in some critical
situations. In our Hospital, the criteria adopted for
this surgery were tumor volume enlargement (due to
proliferation of cancer cells, edema, bleeding or
necrosis) or tumor persistence, causing severe
neurological symptoms, life-threatening situation or
critical steroid dependence (steroid use leading to
severe side effects). Histopathologic evaluation showing
morphologically preserved cancer cells (PCC), often
with necrosis (NEC) or bleeding (BLD), in the specimen
of a surgically treated patient defined the case as a
tumor resistance (recurrence, persistence or
progression).
The aim of this study is to select risk factors for
local failure requiring salvage NS, especially in the case
of tumor resistance.
METHODS
Patients and Treatment Characteristics
From July 1993 to August 2001, 123 patients with 255
brain metastases (newly diagnosed or recurrent) were
submitted to SRS at Hospital Israelita Albert Einstein
in São Paulo, Brazil. We used the F. L. FisherTM
stereotactic treatment planning system, version 2.21
and 3.1X, and a VarianTM 600C linear accelerator
(photon peak energy of 6 MV) for the SRS procedures.
One to 6 lesions were treated per patient per treatment
(median 2 lesions per patient per treatment). Nine
patients were treated twice and two patients were
treated thrice, in a total of 139 procedures. Age ranged
from 28 to 83 years with a median of 61 years (table 1).
Exclusion criteria included: more than 6 lesions, any
lesion larger than 30 cm3, Karnofsky performance status
(KPS) < 50, symptoms requiring urgent neurosurgical
intervention or a very poor overall prognosis owing to
rapid progressive systemic disease.
The most frequent primary tumor was lung
carcinoma (non-small cell carcinoma and small cell
carcinoma), accounting for 45 cases (37%). Twenty-four
patients had malignant melanoma (20%), 19 had breast
adenocarcinoma (15%), 13 had renal clear cell
carcinoma (11%), 10 had colorectal adenocarcinoma
(8%), and 12 patients had other primary tumor
histology (10%). The volume of the treated lesions
ranged from 0.05 cm3 to 28.06 cm3, with a median
volume of 2.70 cm3. Out of the 123 patients, with 255einstein. 2004; 2(1):1-8
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lesions, 44 patients had at least one lesion with the
volume > 5 cm3 (36%) and in the remaining 79 patients
the volume of all lesions was < 5 cm3 (64%) (table 1).
According to lesion size, plan optimization, and
tumor location, the prescribed dose varied from 9 Gy
After this first evaluation, patients were reevaluated
at 3-month intervals during the first year, followed by
4-month intervals during the second year and 6-months
thereafter. Overall survival, local control and disease-
free survival time were evaluated. All clinical events
from the date of SRS to death or last clinical evaluation
until February 2002 were analyzed. The follow-up
period ranged from 6 to 98 months after SRS, and no
patients were lost to follow-up.
Neurosurgery Criteria and Histopathologic
Characteristics
The criteria for salvage NS were volume of tumor
enlargement (due to proliferation of cancer cells,
bleeding or necrosis) or tumor persistence, causing
severe neurological symptoms, life-threatening
situation or critical steroid dependence (steroid use
leading to severe side effects).
The tissue obtained was analyzed and the presence
of PCC at microscopic examination defined the tumor
as having been resistant to SRS (tumor recurrence,
persistence or progression due to cancer cells
proliferation), independently of what demanded
salvage NS (tumor progression or persistence, tumor
necrosis or tumor bleeding). The pathological findings
were thus classified according to their predominance,
as set out in table 2.
Statistical Methods
The Fisher’s exact test was performed to identify risk
factors and their association with active tumor
recurrences in the univariate analysis. All variables that
showed a p value < 0.2, in the univariate analysis, were
tested in a multivariate model using stepwise logistic
regression analysis. Factors retaining significance in the
multivariate model were interpreted as being
independently predictive of active tumor recurrences.
The data were analyzed by the SAS statistical
package(14). All p values reported were two-tailed and
values lower than 0.05 were considered significant.
Results with a p value > 0.05 and < 0.10 were
interpreted as having a trend for association. Odds
ratios and corresponding 95% confidence interval were
calculated. Multivariate logistic regression analysis was
used to assess the influence of risk factors on the local
failure probability using the seven independent
variables tested in the univariate analysis. Significance
levels of 0.20 and 0.10, respectively, were required to
choose and maintain a variable in the model.
Because our objective was to find the patients at
risk of failure, we used number of patients instead of
Table 1. Patients with brain metastases treated with radiosurgery
Period July 1993 – August 2001
Patients & Procedures 123 patients: 70 male / 53 female;
138 procedures; 255 lesions treated
Age 28 to 83 years - Median: 61 years
Primary Tumors Lung carcinoma ……..….…….45 patients (37%)
Malignant melanoma ...………. 24 patients (20%)
Breast adenocarcinoma …...… 19 patients (15%)
Renal carcinoma ……............. 13 patients (11%)
Colorectal adenocarcinoma .... 10 patients (8%)
Other histology ..……………… 12 patients (10%)
Largest Lesion Volume* 0.05 cm3 to 28.06 cm3 – Median: 2.70 cm3
< 5 cm3: 79 cases (64%); > 5 cm3: 44 cases (36%)
Prescribed Radiosurgery Dose* 9 Gy to 22 Gy at 50% to 100% isodose
> 15 Gy: 82 patients (67%) / < 15 Gy: 41 patients (33%)
Median and modal: 18 Gy at 80% isodose
Whole Brain Radiotherapy Total treated patients: 87/123 (71%)
Elective WBRT: 44/123 (36%)
*In case of more than one lesion, the volume and the dose refer to the largest one. SRS: stereotactic
radiosurgery; NS: neurosurgery; WBRT: whole brain radiotherapy.
to 22 Gy, calculated at 50% to 100% of the maximum
dose. The median and modal prescribed dose was 18
Gy, calculated at 80% isodose. Prescribed dose was
more than 15 Gy in 82 cases (67%) and 15 Gy or less in
the remaining 41 patients (33%) (table 1).
Eighty-seven patients (71%) received WBRT at
some phase of their treatment, at the discretion of the
oncology board (table 1). We defined WBRT as an
elective procedure (eWBRT) when this treatment was
completed in the range of two months before or after
SRS. Forty-four patients (36%) received WBRT as an
elective part of the treatment of CNS disease. Although
this treatment was recommended on an individual basis,
patients with two or more brain metastases, primary
tumor other than melanoma or renal cell cancer, age
below 60 years, and without diabetes or peripheral
vascular disease were more likely to receive eWBRT.
The other patients were treated with WBRT as a primary
treatment (without planned SRS) or due to the
progression of the CNS metastatic disease after primary
SRS (without planned WBRT). The treatment
schedule for WBRT was a 30 Gy total dose administered
over two weeks (3 Gy/day, five days/week) for patients
with KPS < 70, and 40 Gy administered over four weeks
(2 Gy/day, five days/week) for patients with KPS > 70.
The follow-up included clinical and image
examinations. General physical and neurological
examinations, in addition to contrast-enhanced CT or
MRI, were performed at 4 to 6 weeks after treatment.einstein. 2004; 2(1):1-8
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number of lesions in our statistical analysis. Primary
tumor histology (melanoma vs. other; and breast vs.
other), WBRT (all WBRT and eWBRT), SRS
prescribed dose (< 15 Gy vs. > 15 Gy), and brain lesion
volume (< 5 cm3 vs. > 5 cm3) were tested in order to
assess the relative risk of local failure requiring salvage
NS. We analyzed each factor divided in primary tumor
histology, WBRT, SRS dose, and tumor volume (table
3 and table 4). These factors were submitted to
univariate (table 5) and multivariate analysis (table 6).
RESULTS
The clinical and treatment characteristics of the 123
patients are summarized in table 1. The actuarial
median survival was 8.3 months (figure 1). Fourteen of
those patients (11%) required salvage NS, and eleven
(9%) showed PCC on histopathologic evaluation. The
remaining three (2%) showed only NEC (table 2).
Necrosis (with or without PCC) was the main
component in half (7/14) of the cases, PCC in six cases
(6/14), and in one case (table 2) the main reason for
local failure was bleeding, resulting in a rescue NS
three weeks after SRS (table 2, patient 11).
The median volume of metastatic lesions was 2.7
cm3 in the 123 analyzed patients, 3.7 cm3 in the
melanoma group, 2.4 cm3 in the operated group, and
4.1 cm3 in the active tumor group (table 3). Out of the
123 patients, with 255 lesions, 44 patients had at least
one lesion with the volume > 5 cm3 (36%), and in the
remaining 79 patients, the volume of all lesions was <
5 cm3 (64%) (table 1). The incidence of rescue NS was
11% in both groups, with 11% of PCC in the former
group and 8% in the latter (table 4).
The RS median prescribed dose was 18 Gy in the
123 analyzed patients and in the melanoma group, 17
Gy in the operated group, and 15 Gy in the active tumor
group (table 3). In the group of patients receiving 15
Gy or less (41/123: 33%), 15% (6/41) were operated on
and all presented PCC. In the remaining group,
receiving more than 15 Gy (82/123: 67%), only 10% (8/
82) were operated on and 6% (5/82) presented PCC
(table 4).
Of the 123 patients, 87 (71%) were treated with
WBRT as part of the central nervous system treatment,
and 44 patients (44/123: 36%) had WBRT as an elective
procedure. WBRT was applied to 71% (17/24) of the
patients presenting melanoma, and electively in 42%
Table 2. Patients requiring salvage neurosurgery after radiosurgery
Primary Tumor Whole Brain Elective Whole Largest Lesion Radiosurgery Histopathological
# Histology Radiotherapy Brain Volume* Dose* Findings**
Radiotherapy
1 Melanoma Yes No 0.4 cm3 20 Gy NEC + PCC
2 Melanoma Yes Yes 5.1 cm3 18 Gy PCC + NEC
3 Melanoma No No 4.07 cm3 18 Gy PCC + NEC
4 Breast Yes Yes 1.3 cm3 18 Gy NEC
5 Breast No No 0.1 cm3 18 Gy NEC
6 Breast Yes Yes 2.7 cm3 15 Gy PCC + NEC + BLD
7 Breast Yes No 2.1 cm3 15 Gy PCC + NEC
8 Bladder Yes No 5.8 cm3 15 Gy PCC + NEC
9 Lung Yes No 2 cm3 15 Gy NEC + PCC
10 Kidney No No 0.1 cm3 18 Gy NEC
11 Fibrous histiocytoma No No 19.8 cm3 15 Gy BLD + PCC
12 Melanoma No No 11.7 cm3 15 Gy NEC + PCC
13 Melanoma No No 0.6 cm3 18 Gy PCC + BLD + NEC
14 Breast No No 5.1 cm3 16 Gy NEC + PCC
*In case of more than one lesion, only the largest one was considered for volume and dose evaluation; **Histopathological data in order of predominance: PCC: preserved cancer cells; NEC: necrosis; BLD:
bleeding.
Table 3. Data from patients with brain metastases treated with radiosurgery, requiring salvage neurosurgery or not, and the correlation between treatment
and tumor variables
All patients Melanoma Breast Operated on Active Tumor*
WBRT 87/123 (71%) 17/24 (71%) 16/19 (84%) 7/14 (50%) 6/11 (55%)
Elective WBRT 44/123 (36%) 10/24 (42%) 8/19 (42%) 3/14 (21%) 2/11 (18%)
Volume (Median) 2.7 cm3 3.7 cm3 2.2 cm3 2.4 cm3 4.1 cm3
SRS dose (Median) 18 Gy 18 Gy 15 Gy 17 Gy 15 Gy
*Histopathological specimen showing active cancer cells.einstein. 2004; 2(1):1-8
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(10/24) of them (table 2 and table 3). Thus, when
compared with the total accrual, a similar percentage
of melanoma patients received both WBRT (71% vs.
71%) and eWBRT (36% vs. 42%). Seven out of the 14
operated patients (50%) received WBRT, but only three
(21%) as an elective procedure (table 3). WBRT was
applied to six of the eleven PCC patients, but electively
only in two (18%) of them (table 3). Only 2 out of the
44 eWBRT patients (4%) presented PCC, versus 14%
(5/36) in the group never treated with WBRT (table 4).
The primary tumor histology among the 14 operated
patients was melanoma in five cases (21% of the
melanoma patients), breast cancer in five cases (26%
of the breast cancer patients), and other tumors in the
four remaining cases. Of the 11 cases with active
neoplasia, five were melanoma (20% of the melanoma
patients), three were breast cancer (16% of the breast
cancer patients), and the three remaining cases were
other tumors. All five patients with melanoma that were
operated on had PCC in their surgical specimen, and
only 6% (6/99) of the non-melanoma patients had this
finding (table 4).
The Fisher’s exact test and logistic regression were
applied in the univariate analysis of the association
between risk factors and local failure (table 5). Non-
significant predictors included SRS prescribed dose (=
15 Gy vs. > 15 Gy), and volume (< 5 cm3 vs. > 5 cm3).
Malignant melanoma, as the primary histology, was the
only statistically significant risk factor associated with
local tumor recurrence (p=0.0381; two-sided Fisher’s
exact test). Melanoma cases had four times greater
Table 4. Radiosurgery for brain metastases: risk factors for salvage neurosurgery and local failure
Risk Factors For Salvage Neurosurgery Total* Operated on** Active Tumor#
Primary Tumor Histology
Melanoma 24/123 (20%) 5/24 (21%) 5/24 (21%)
Other  99/123 (80%) 9/99 (9%) 6/99 (6%)
Primary Tumor Histology
Breast 19/123 (15%) 5/19 (26%) 3/19 (16%)
Other  104/123 (85%) 9/104 (9%) 8/104 (8%)
Whole Brain Irradiation
No 36/123 (29%) 7/36 (19%) 5/36 (14%)
Total 87/123 (71%) 7/87 (8.0%) 6/87 (7%)
Elective 44/123 (36%) 3/44 (6.8%) 2/44 (4%)
Prescribed Radiosurgery Dose##
< 15 Gy 41/123 (33%) 6/41 (15%) 6/41 (15%)
> 15 Gy 82/123 (67%) 8/82 (10%) 5/82 (6%)
Volume##
< 5 cm3 79/123 (64%) 9/79 (11%) 6/79 (8%)
> 5 cm3 44/123 (36%) 5/44 (11%) 5/44 (11%)
*All 123 patients were considered; **14 operated on patients; #11 patients operated on with histopathological specimen showing active cancer cells; ##In case of more than one lesion, only the largest one
was considered.
Figure 1. Kaplan-Meier actuarial survival curve for the 123 studied patients.
Table 5. Risk factors for local failure*: univariate analysis
Risk Factors For Salvage Neurosurgery p-value** Odds Ratio 95% CI#
Primary Histology (Melanoma vs. Other) 0.0381 4.08 1.13 – 14.75
Primary Histology (Breast vs. Other) 0.3733 2.25 0.54 -9.34
Whole Brain Irradiation (Yes vs. No) 0.2962 0.46 0.13 – 1.61
Elective Whole Brain Irradiation (Yes vs. No) 0.3246 0.37 0.08 – 1.80
Radiosurgery Prescription Dose## (> 15 Gy vs. < 15 Gy) 0.1774 0.38 0.11 – 1.32
Volume## (< 5 cm3 vs. > 5 cm3) 0.5205 1.56 0.45 – 5.44
*Patients operated on with histopathological specimen showing active cancer cells. **Significance: p<0.05, two-sided Fisher´s exact test; #95% CI: 95% confidence interval; ##In case of more than one
lesion, only the largest one was considered.einstein. 2004; 2(1):1-8
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probability (OR = 4.08; 95% CI = 1.13-14.75) of
developing local tumor recurrence than non-melanoma
cases (table 5).
We also applied multivariate stepwise logistic
regression analysis to assess the influence of the
following risk factors on brain tumor recurrence: SRS
prescribed dose, lesion volume, WBRT, eWBRT, and
primary histology. This procedure (table 6) identified
a final predictive model limited to an increased risk of
local tumor recurrence among patients with melanoma,
compared to those with other primary histology (p =
0.321; OR = 4.08; 95% CI = 1.13-14.75). A p value of
0.98 was obtained through Hosmer-Lemeshow
Goodness-of-Fit Test implying that the model was
adequate to data analysis.
DISCUSSION
The role of focal treatment for brain metastases has
been challenged in the last two decades and the option
between NS and SRS is still controversial(15-16). Surgical
excision remains an important therapy for selected
patients with large tumors(15) or symptomatic patients(6)
and provides a specimen for histopathological
evaluation. Surgery has been used in the treatment of
brain metastases for many years and the major
advantage of this procedure is the immediate relief of
neurological signs and symptoms(6). Patients with
solitary brain metastasis, controlled primary tumor, no
evidence of systemic disease, non-radiosensitive primary
tumor, and good performance status (Karnofsky > 70),
are the best candidates for surgical resection and
WBRT. These patients have shown both longer survival
and longer functional independence than patients
treated with WBRT alone(17).
One of the largest studies on surgical resection for
brain metastases was performed at the Memorial Sloan-
Kettering Cancer Center between January 1974 and
December 1993. The clinical course of 709 patients
submitted to resection of brain metastases was analyzed
in 7 papers, dividing the accrual according to the
primary tumor: malignant melanoma(18), renal cell
carcinoma(19), sarcoma(20), non-small cell lung cancer
(NSCLC)(21), breast carcinoma(22), and colorectal
carcinoma(23). The survival of patients with recurrent
brain disease from colorectal and NSCLC was also
analyzed(23-24). The results, with some particular features
in each clinical situation, indicated that surgical
resection in a selected subset of patients is effective in
providing local tumor control, prolonging survival and
preserving quality of life, independently of the primary
tumor histology(24-30).
In the 80’s, the role of SRS in the treatment of
brain metastases was demonstrated(13). Twelve
inoperable and radioresistant lesions were treated using
a modified linear accelerator, with single fraction doses
ranging from 20 Gy to 30 Gy. These lesions had a
reduction of the enhancing volume and edema, with
improvement of motor and sensorial deficits. Loeffler
et al.(11), treating recurrent brain metastases, confirmed
these data. They reported dramatic and rapid
neurological and radiological responses in their series,
achieving local control in all patients, with a median
follow-up period of 9 months. The neurological
improvement provided prolonged survival and better
quality of life(10).
SRS has been used for the treatment of small brain
metastases with positive results(2-4,10). A revision of 116
patients with solitary brain metastases who underwent
gamma knife SRS at five institutions, concluded SRS
is effective in controlling single brain metastases(2).
Surgical resection of the tumor treated by radiosurgery
due to hemorrhage, necrosis, or tumor recurrence was
performed in ten patients (8.6%)(2). They also found
that eWBRT had favorable results regarding local
tumor control in melanoma and renal cell brain
metastases, both at univariate and multivariate
analysis(25).
At the Tokyo Women’s Medical Center, a local
control rate of 82% was achieved during a mean follow-
up period of 5.5 months(8), whereas in the 16-year
experience of the Karolinska Institute, local control
reached 94%(9). Less than 10% of these patients died
from progression of SRS-managed tumor(8,12) or from
secondary neurological disease(10). SRS was as effective
as surgery in providing local control, with the advantage
of allowing the treatment of surgically inaccessible
lesions and multiple metastases(7). Mehta et al.(16)
compared the outcome of 454 patients with single brain
metastases submitted to WBRT alone (181 cases), SRS
(135 patients) or NS (46 cases). They found that either
resection or SRS yielded superior survival and
functional independence, with minor differences in
outcome between the two modalities. Resection
Table 6. Risk factors for local failure*: multivariate logistic regression analysis
Variable Logistic Coefficient p-value* Odds Ratio 95% CI#
Primary Histology (Melanoma vs. Other) 0.7029 0.0321 4.08 1.13 – 14.75
*Patients operated on with histopathological specimen showing active cancer cells. **Significance: p < 0.05; #95% CI: 95% confidence interval.einstein. 2004; 2(1):1-8
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resulted in a 1.8-fold increase in cost and they concluded:
“SRS appears to be the most cost-effective procedure”.
The RTOG 9508 phase III trial, comparing WBRT
alone versus WBRT plus SRS for 333 patients with
brain metastases demonstrated significant difference
in overall survival between these two groups in each of
the following categories:
1. solitary brain metastases;
2. RPA class I (group of patients with the best prognosis)(33)
3. age < 50;
4. non-small lung cancer and any squamous cell
carcinoma.
The results of this study showed that all subsets of
patients in the eWBRT + SRS group were more likely
to have a stable or improved performance status than
those in the WBRT alone group. The one-year local
control was 82% in the WBRT plus SRS group and
71% in the WBRT alone group (p=0.01), suggesting a
better quality of life in the former group of patients(26).
Thus, focal therapy (SRS and NS) with or without
WBRT may control brain metastases improving quality
of life, and perhaps survival time. SRS is more cost-
effective(16) and less restricted by location, number of
lesions, performance status, or general medical
condition(7). NS has the advantages of faster symptom
relief and of providing material for definitive
histological diagnosis(6). The choice of the best focal
treatment is still not completely defined, depending,
in many cases, on the skills of the specialized center
team and personal preference. The knowledge of the
risk factors for local failure after SRS may help in the
general management of these patients and in the
decision-making process between SRS and NS.
Central nervous system failure after radiosurgery for
brain metastases is associated with many risk factors in
the medical literature. The most frequently reported
risks are volume of treated lesion(4,7-8,27-30), SRS
dose(27-31), eWBRT(2,28,32-33), and primary tumor
histology(4,6,18,34). Recurrent metastases are considered
less responsive to SRS than newly diagnosed ones(7).
The pattern of enhancement is also related to local
control, with the ring-enhancing lesions having a lower
probability of being controlled than the homogeneous-
enhancing lesions(27-31).
Although in this study the median volume of all
255 treated lesions was 2.7cm3 and 4.1 cm3 in cases of
PCC (table 3), volume was not statistically associated
with local recurrence (table 5). SRS dose > 15 Gy
resulted in only 6% of local failure and = 15 Gy in
15% (table 4), suggesting that SRS dose may be
associated with local control, but both univariate and
multivariate statistical analysis were negative for this
hypothesis (table 5 and table 6).
Avoiding eWBRT in the treatment of patients with
brain metastases may be associated with tumor
recurrence, both at the site of SRS and elsewhere in
the brain(28,32-36). In addition to this fact, the use of
primary SRS alone was associated with an increased
probability of neurological deficit and worsening of
the quality of life, especially if the metastatic disease
is confined to the brain(28). However, Wronski and Arbit
found a comparable incidence of brain tumor
recurrences with or without eWBRT after surgical
excision of malignant melanoma brain metastases(18).
Although a trend for improved local control was
observed among patients treated with WBRT in this
study (table 3 and table 4), this association did not
reach statistical significance either in the univariate,
or in the multivariate analysis. We did not analyze
quality of life, but an increased tendency for salvage
NS may have negative impact on the life quality of
patients not treated with WBRT.
Several authors showed that the local control rate
of brain metastases from malignant melanoma treated
with SRS is similar(7,10,12,25,30), or even better(3) than other
primary tumors, and dependent on the applied
dose(7,10,25,30) and on the metastatic tumor volume(12,29).
After SRS, 90% of the treated lesions were considered
controlled, including persistent lesions that did not
cause major symptoms(12-31). McWilliams et al., reviewing
the medical literature on this subject, conclude that
SR is less invasive than NC, and is an attractive option
for patients with solitary or oligometastatic brain
lesions(37). Others, concluded that local control is worse
for melanoma patients when compared to other
patients(27,31,34), even applying higher SRS doses(34).
Petrovich et al, concluded that patients with brain
metastases from melanoma have a different pattern of
failure when compared with those with other
diagnoses. In this study, the cause of death in patients
with melanoma was in 50% of the cases due to systemic
disease, and 42% due to central nervous system causes,
whereas it was 70% for the former and 23% for the
latter in patients with other diagnoses(35).
In our study, the probability of local failure leading to
salvage NS after SRS was significantly increased in patients
with brain metastases from malignant melanoma, both in
univariate (p = 0.0381) and multivariate analysis (p =
0.0321). The explanation for this higher rate of local failure
is not clear, and may be considered secondary to the
malignant melanoma relative radioresistance(38) or to its
increased probability of bleeding(36). But, in this study,
the only case in which bleeding was directly correlated to
local failure needing salvage NS was a patient with a
malignant fibrous histiocytoma, weakening the latter
hypothesis in our accrual.einstein. 2004; 2(1):1-8
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We conclude that the risk of local failure leading
to salvage NS after SRS is greater in patients with
malignant melanoma. Our data also suggest that all
patients with brain metastases treated with SRS might
benefit from eWBRT, owing to a trend for decreased
local failure and consequent salvage NS.
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